231 related articles for article (PubMed ID: 32798715)
1. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma.
Xu F; Zhan X; Zheng X; Xu H; Li Y; Huang X; Lin L; Chen Y
Genomics; 2020 Nov; 112(6):4675-4683. PubMed ID: 32798715
[TBL] [Abstract][Full Text] [Related]
2. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
5.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
6. A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients.
Jiang P; Li Y; Xu Z; He S
Transl Oncol; 2021 Jan; 14(1):100924. PubMed ID: 33221687
[TBL] [Abstract][Full Text] [Related]
7. Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses.
Liu Y; Zhang X; Pang Z; Wang Y; Zheng H; Wang G; Wang K; Du J
Aging (Albany NY); 2024 May; 16(10):8772-8809. PubMed ID: 38771130
[TBL] [Abstract][Full Text] [Related]
8. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma.
Ling B; Huang Z; Huang S; Qian L; Li G; Tang Q
Oncol Res; 2021 Mar; 28(6):561-578. PubMed ID: 32471520
[TBL] [Abstract][Full Text] [Related]
10. Development of an immune-related gene pairs signature for predicting clinical outcome in lung adenocarcinoma.
Wu C; Hu Q; Ma D
Sci Rep; 2021 Feb; 11(1):3611. PubMed ID: 33574499
[TBL] [Abstract][Full Text] [Related]
11. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
12. CD8
Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
Front Immunol; 2022; 13():806877. PubMed ID: 35273597
[TBL] [Abstract][Full Text] [Related]
13. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
Peng X; Wu H; Zhang B; Xu C; Lang J
Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
[TBL] [Abstract][Full Text] [Related]
14. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
15. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
16. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
Liao Y; He D; Wen F
Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518
[TBL] [Abstract][Full Text] [Related]
17. A novel signature based on immune-related gene pairs and clinical features to predict prognosis and treatment effect in "driver gene negative" lung adenocarcinoma.
Cai HY; Yang HS; Shan SC; Lei YY; Zou JY; Zhu Y; Luo HH
Cancer Med; 2022 Jun; 11(11):2259-2270. PubMed ID: 35246970
[TBL] [Abstract][Full Text] [Related]
18. Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma.
Li Y; Tao L; Cai W
Biomed Res Int; 2020; 2020():5858092. PubMed ID: 32596334
[TBL] [Abstract][Full Text] [Related]
19. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
20. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
